Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer



Summary

Activation of the PPARγ pathway shows promise in improving CAR T cell therapy for bladder cancer. Research indicates that stimulating PPARγ leads to increased expression of NECTIN4, a protein target for CAR T cells, on bladder cancer cells. This upregulation of NECTIN4 makes the cancer cells more susceptible to CAR T cell attack. By enhancing the expression of the target antigen, PPARγ modulation improves the effectiveness of CAR T cell therapy, potentially leading to better outcomes for patients with bladder cancer. The findings suggest a novel strategy to overcome resistance and enhance the efficacy of CAR T cell immunotherapy.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!